Literature DB >> 10755262

Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis?

R Testa1, U Valente, D Risso, S Caglieris, E Giannini, A Fasoli, F Botta, G Dardano, P B Lantieri, G Celle.   

Abstract

BACKGROUND: Liver transplantation is nowadays the therapeutic option for end-stage liver disease. Correct disease staging is the main step towards improving the timing of listing for liver transplantation so as to avoid premature or late entry. The need for correct prognostic evaluation is due to the limited number of donors and to the increasing number of patients awaiting transplantation. Our aim was to verify whether Child-Pugh's score might be improved by adding the monoethylglycinexylidide (MEGX) formation test and/or serum bile acid determination.
METHODS: We evaluated 182 cirrhotic patients (44 Child-Pugh class A, 97 class B, and 41 class C) of mixed aetiology referring to a tertiary care centre for functional staging of liver disease. These patients were prospectively followed-up for 12-72 months. During this period, 45 patients died, 46 received a transplant, and 91 survived without transplantation. The end-point of analysis was either survival or liver disease-related death at the 6th, 12th, 18th and 24th months of follow-up. The 46 transplanted patients were excluded from the study upon transplantation.
RESULTS: In our study, a cut-off for Child-Pugh's score < 8 confirmed its usefulness, especially in short-term prognostic prediction, while mid- and long-term prediction improved by almost 10% by using the combination of a Child- Pugh's score > 8 and an MEGX value < 15 mg/l. Cox's multi-variate regression analysis indicated that MEGX values either with Child-Pugh's score or with prothrombin activity and ascites were independent prognostic variables.
CONCLUSIONS: Besides confirming that Child-Pugh's score as the basis of prognostic evaluation of cirrhotic patients, these results suggest that the MEGX test might be a complement to the original score when a patient is being evaluated for a liver transplantation programme.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10755262     DOI: 10.1097/00042737-199905000-00016

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  11 in total

1.  MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study.

Authors:  F Botta; E Giannini; P Romagnoli; A Fasoli; F Malfatti; B Chiarbonello; E Testa; D Risso; G Colla; R Testa
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

2.  Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis.

Authors:  Xiaoning Wang; Guoxiang Xie; Aihua Zhao; Xiaojiao Zheng; Fengjie Huang; Yixing Wang; Chun Yao; Wei Jia; Ping Liu
Journal:  J Proteome Res       Date:  2016-03-22       Impact factor: 4.466

3.  Predicting morbidity and mortality after hepatic resection in patients with hepatocellular carcinoma: the role of Model for End-Stage Liver Disease score.

Authors:  Kuang-Yu Hsu; Gar-Yang Chau; Wing-Yiu Lui; Shyh-Haw Tsay; Kuang-Liang King; Chew-Wun Wu
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

4.  Application of a biochemical and clinical model to predict individual survival in patients with end-stage liver disease.

Authors:  Eduardo Vilar Gomez; Luis Calzadilla Bertot; Bienvenido Gra Oramas; Enrique Arus Soler; Raimundo Llanio Navarro; Javier Diaz Elias; Oscar Villa Jiménez; Maria del Rosario Abreu Vazquez
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

5.  Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality.

Authors:  Swee H Teh; John Christein; John Donohue; Florencia Que; Michael Kendrick; Michael Farnell; Stephen Cha; Patrick Kamath; Raymond Kim; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2005-12       Impact factor: 3.267

6.  Urinary metabolite profiling offers potential for differentiation of liver-kidney yin deficiency and dampness-heat internal smoldering syndromes in posthepatitis B cirrhosis patients.

Authors:  Xiaoning Wang; Guoxiang Xie; Xiaoyan Wang; Mingmei Zhou; Huan Yu; Yan Lin; Guangli Du; Guoan Luo; Ping Liu
Journal:  Evid Based Complement Alternat Med       Date:  2015-01-18       Impact factor: 2.629

7.  Systemic vascular resistance in cirrhosis: a predictor of severity?

Authors:  Vinaya Gaduputi; Molham Abdulsamad; Sailaja Sakam; Naeem Abbas; Hassan Tariq; Ariyo Ihimoyan
Journal:  Hepat Med       Date:  2014-08-06

8.  Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma.

Authors:  Reham Abdel-Wahab; Samir Shehata; Manal M Hassan; Lianchun Xiao; Ju-Seog Lee; Sheree Cheung; Hoda H Essa; Hesham M Hassabo; Ahmed S Shalaby; Eman Mosad; Kanwal Raghav; Asif Rashid; Robert A Wolff; Jeffrey S Morris; Hesham M Amin; Ahmed O Kaseb
Journal:  Oncotarget       Date:  2015-08-28

9.  Validation of a Modified Child-Turcotte-Pugh Classification System Utilizing Insulin-Like Growth Factor-1 for Patients with Hepatocellular Carcinoma in an HBV Endemic Area.

Authors:  Dong Hyeon Lee; Jeong-Hoon Lee; Yong Jin Jung; Jungsoo Gim; Won Kim; Byeong Gwan Kim; Kook Lae Lee; Yuri Cho; Jeong-Ju Yoo; Minjong Lee; Young Youn Cho; Eun Ju Cho; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

10.  Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.

Authors:  Ahmed O Kaseb; Lianchun Xiao; Manal M Hassan; Young Kwang Chae; Ju-Seog Lee; Jean-Nicolas Vauthey; Sunil Krishnan; Sheree Cheung; Hesham M Hassabo; Thomas Aloia; Claudius Conrad; Steven A Curley; John M Vierling; Prasun Jalal; Kanwal Raghav; Michael Wallace; Asif Rashid; James L Abbruzzese; Robert A Wolff; Jeffrey S Morris
Journal:  J Natl Cancer Inst       Date:  2014-05-09       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.